Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:40:47.936Z.
Calculation as of: 2026-10-06T19:40:47.936Z.
Quote observation: 2026-10-06T19:39:39.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b8a0cb47064437e8b9c77c3ec53eeb060705b9d611480c07f1c1fa4a72564033
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
bioAffinity Technologies, Inc.
Market Cap
$2.54M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | $2.54M | N/A |
| Nuwellis, Inc. (NUWE)vs › | $2.58M | N/A |
| Jaguar Health, Inc. (JAGX)vs › | $2.47M | N/A |
| Onconetix, Inc. (ONCO)vs › | $2.37M | N/A |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.38M | N/A |
| iSpecimen Inc. (ISPC)vs › | $2.72M | N/A |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.39M | N/A |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.40M | N/A |
| Universe Pharmaceuticals Inc. (UPC)vs › | $2.75M | N/A |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.30M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
